On 26 August 2013 the Chiesi Group reached an agreement for the acquisition of the company Zymenex Holding A/S, a pharmaceutical biotechnology group that focuses on the research and development of innovative biological treatments, for rare and life-threatening genetic illnesses. Zymenex Holding A/S is the parent company of Zymenex A/S (www.zymenex.com), a Danish pharmaceutical biotechnology company founded in 1998 with head offices in Hillerod north of Copenhagen and research labs in Stockholm.
On 26 August 2013 the Chiesi Group reached an agreement for the acquisition of the company Zymenex Holding A/S, a pharmaceutical biotechnology group that focuses on the research and development of innovative biological treatments, for rare and life-threatening genetic illnesses. Zymenex Holding A/S is the parent company of Zymenex A/S (www.zymenex.com), a Danish pharmaceutical biotechnology company founded in 1998 with head offices in Hillerod north of Copenhagen and research labs in Stockholm.
According to our strategic orientation to orphan diseases, Zymenex represents an important opportunity for Chiesi to enter the world of very rare metabolic diseases.
In the Zymenex portfolio, Lamazym is indicated for use in Alpha-mannosidosis patients, a genetic disorder that causes progressive central nervous system deterioration and two other pre-clinical phase molecules for other extremely rare diseases.
“We are excited to announce this acquisition”, said Ugo Di Francesco, Chief Executive Officer of the Chiesi Group. “It will enable us to expand our know-how in research and development, to register new and developing drugs in our portfolio, to develop our international presence and to increase our competitiveness. Given the rarity of the illnesses and the importance of being close to patients, we will look into the case of developing an autonomous unit for rare diseases”.
We warmly welcome the Zymenex team consisting of a group of 15 researchers specializing in the synthesis of proteins and recombinant enzymes. This is an important first step in developing our competitiveness in the field of biological products.
